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Hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV are blood-
borne infections that share common routes of transmission. The main 
modes of transmission of HBV and HIV are from mother to child, 
horizontal in early childhood, and from unprotected sexual contact, 
sharing of sharps and injection drug abuse. HCV is transmitted 
mostly through direct contact with the blood of an infected person 
via blood transfusion and intravenous drug use.[1] The prevalence of 
mono-infection and co-infection is therefore common, especially in 
low- and middle-income countries in South-East Asia and Africa.[2,3]
Globally, it is estimated that 2 billion persons have previous or 
current evidence of HBV infection, of whom 400 million are chroni-
cally infected.[4] HCV and HIV affect 170 million and 33  million 
persons, respectively.[3] Of the 33 million people living with HIV 
worldwide, 5 - 20% have chronic HBV infection and 5 - 15% hepa-
titis C infection, although the rate of hepatitis C infection may rise to 
90% among people who inject drugs.[1] Of people living with HIV in 
the USA, ~25% are co-infected with HCV and ~10% are co-infected 
with HBV.[5]
Nigeria is hyperendemic for HBV, with a prevalence of 12%, but has 
a relatively low prevalence of HCV of 0.5 - 4% and a 3.1% prevalence 
of HIV. However, with a population of 170 million according to the 
2006 census, this translates to approximately 23 million of its general 
population living with HBV, 1 - 6 million living with HCV and 
3.5  million living with HIV.[6-8] The consequences of infection with 
these viruses, including hepatocellular carcinoma and liver cirrhosis, 
are responsible for >20% of mortality in Nigeria.[9] Cross River State 
(CRS), located in the Niger delta region of Nigeria, is thought to have 
among the highest prevalence rates of HIV, HBV and HCV in the 
country.[10,11]
Treatment options for individuals with chronic hepatitis B, C or 
HIV infection have improved considerably in the last few years. 
For HBV and HIV, the use of nucleoside or nucleotide analogues 
in addition to protease inhibitors (for HIV) leads to suppression of 
the virus in most patients and prevents transmission and onset of 
complications.[12] For HCV, the discovery of direct antiviral agents 
has transformed the disease from an incurable to a potentially 
curable condition with sustained virological response of >90% even in 
patients with advanced liver disease.[13,14] Bearing in mind the benefits 
of these treatment options, it is imperative to identify individuals 
who are infected with these viruses by providing effective screening 
programmes, and to initiate therapy if indicated. It is noteworthy that 
the USA and some countries in Europe recommend population-based 
screening of adults for HCV and risk-based screening for HBV.[15,16]
The Nigerian Society for Gastroenterology and Hepatology in 
the hepatitis B and C treatment guideline published in 2015[7] also 
recommends population-based screening of all adults for HBV, 
with opportunities to screen at any visit to a healthcare facility, 
ante natal care, preschool and pre-employment, among others. Risk-
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based screening is recommended for HCV, and the suggested target 
population includes persons who abuse injection drugs, healthcare 
workers, persons with sexually transmitted infections, especially HIV, 
and children born to HCV-positive mothers.[7] The Federal Ministry 
of Health had earlier adopted population-based voluntary counselling 
and testing for HIV, which has greatly contributed to reduction of 
the national prevalence of HIV from 8% in 2006 to 3.5% in 2013. [17] 
Most prevalence data on HBV and HCV in Nigeria are hospital 
based, among cohorts of either patients with liver disease or blood 
donors. [11,18] The same applies to data on HIV prevalence in Nigeria, 
which have largely been derived from sentinel studies among pregnant 
women and other people presenting for care in health facilities.[19,20] It 
is vital to acquire population-based data on the prevalence of these 
blood-borne viruses to inform optimal national control strategies.
Objective
To determine the population-based prevalence of hepatitis B and C 
viruses and HIV and risk factors for infection with these viruses in 
CRS, Nigeria.
Methods
Study area
The study was conducted in CRS, located in the coastal region 
of Nigeria. The state occupies 20 156 km2 and shares a boundary 
with the Republic of Cameroon. According to the 2006 national 
census, CRS had a total population of 2 892 988, with 1 471 967 
males and 1 421 021 females.[6] CRS is divided into three senatorial 
districts (southern, central and northern) and 18 local government 
areas (LGAs), six per senatorial district. They are Abi, Akamkpa, 
Akpabuyo, Bakassi, Bekwarra, Biase, Boki, Calabar Municipal, Cala-
bar South, Etung, Ikom, Obanliku, Obubra, Obudu, Odukpani, 
Ogoja, Yakuur and Yala.
Study design
The study was a cross-sectional analytical study conducted between 
March 2015 and August 2016.
Study population
The study population consisted of residents of CRS aged ≥18 years. 
Each respondent provided written informed consent. Individuals 
aged <18 years and those who refused to give consent were excluded 
from the study.
Sample size calculation
The minimum sample size for this study was 1 620, which was 
calculated using the formula:
    n = z2p (1 – p)/d2
where z = confidence interval (CI) of 95%, p = prevalence rate of 
hepatitis B infection taken as 12%,[18] and d = the desired precision, 
which was 5%.
Sampling technique
A multistage sampling method was used to recruit participants.
• Stage 1. In each senatorial district, three LGAs were randomly 
selected by balloting. The selected LGAs were Calabar south, 
Akpabuyo, Akamkpa, Abi, Yakurr, Ikom, Obudu, Ogoja and Yala.
• Stage 2. In each selected LGA, three wards were further selected 
randomly by balloting.
• Stage 3. A total of 60 participants were recruited from each ward.
Advocacy visits to community leaders were carried out and com-
munity mobilisation was conducted to sensitise the residents prior to 
the screening exercise.
Data collection
A structured questionnaire, pretested for reliability and validity and 
including demographic data (age, sex and family size), past/present 
symptoms of liver disease, and exposure to risk factors associated 
with acquisition of the hepatitis/HIV viruses was administered to 
each participant.
Laboratory investigations
Three millilitres of venous blood was collected from each participant 
into a clean plain bottle, allowed to clot and then centrifuged at 
3 000 rpm for 10 minutes. The supernatant serum was harvested 
and pipetted into cryotubes, which were stored at –20oC till the 
time of batch analysis. Each sample was tested for HBV, HCV 
and HIV using an enzyme-linked immunosorbent assay (ELISA) 
technique with assay kits manufactured by DRG International Inc. 
(USA). The hepatitis B surface antigen (HBsAg) ELISA kit utilises 
horseradish peroxidase (HRP)-conjugated anti-human IgG and 
multiple recombinant HBsAg antigens to detect HBsAg in serum 
samples. Test results were interpreted as a ratio of the absorbance of 
the sample (As) and the absorbance of the negative control (An), an 
As/An ratio of <2.10 indicating a negative result and a ratio of ≥2.10 
a positive result. Assay sensitivity and specificity were both >97.5%.
Sera were also tested for anti-HCV IgG antibodies using a 
sandwich ELISA technique. The HCV ELISA test kit utilises HRP-
conjugated anti-human IgG and multiple recombinant HCV antigens 
to detect anti-HCV IgG antibodies in serum samples. Test results 
were interpreted as the ratio of the absorbance of samples and cut-off 
absorbance (COV), determined as the mean of the absorbances of 
two negative control sera + 0.15. A ratio of <1.0 indicates a negative 
result (absence of anti-HCV IgG antibodies) while a ratio of ≥1.0 
indicates a positive result (presence of detectable anti-HCV IgG 
antibodies in serum samples).
HIV 1 and 2 antibodies were tested for using a sandwich ELISA 
technique. The test kit utilises HRP-conjugated HIV antigen 
and recombinant HIV antigen coated on micro-wells to detect 
anti-HIV antibodies present in serum samples. Test results were 
interpreted based on the calculated COV determined as the average 
of absorbances of two negative control sera + 0.1. Samples with 
absorbances ≥COV absorbance were reported as positive, while those 
with absorbance <COV absorbance were reported as negative. Assay 
sensitivity, specificity and imprecision were ≥97.5%, ≥97.5%, and 
≤15.0%, respectively.
Statistical analyses
Stata version 14 (StataCorp, USA) was used for the data analyses. The 
Kolmogrov-Smirnov test was used to test the nature of distribution 
of continuous variables. Median values were calculated for skewed 
continuous variables, while categorical variables were presented 
in percentages. Bivariate analyses (χ2 and Fisher’s exact tests) were 
used to compare differences in sociodemographic characteristics 
and other categorical attributes. Risk factors that were significantly 
associated with HBV, HCV and HIV infections were analysed by 
forward selection and used to model the multivariate (adjusted) 
binary logistic regression analysis at a 5% level of significance. Risk 
factors that were not significantly associated (CIs including the null 
value of 1) with HBV, HCV and HIV infections were excluded in the 
final adjusted model. The multiple imputations by chained equations 
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approach for categorical variables was used to impute for risk factors 
with missing observations.
Ethics approval
Ethics approval was obtained from the CRS Health Research Ethics 
Committee (ref. no. RP/REC/2015/281).
Results
A total of 1 498 subjects were recruited from the three senatorial 
districts in CRS. The southern, central and northern districts 
contributed 536 (35.8%), 445 (29.7%) and 517 (34.5%) of the study 
population, respectively. The median age of the study population 
was 39 years (interquartile range (IQR) 27 - 50), and was higher for 
individuals from the central district than for those from the southern 
and northern districts (40 years v. 35 years; p=0.001). There were 
more females than males (average ratio 1.7:1), the variation in gender 
ratio being more pronounced in the central district (2.1:1) than in the 
southern and northern districts (1.9:1 and 1.3:1). The majority of the 
participants were married, had a formal education (usually a tertiary 
education), and came from households with ≥5 members. Further 
characteristics of the study population are summarised in Table 1.
Characteristics of HBsAg-positive subjects
A total of 1 365 samples were assayed for HBsAg. The prevalence of 
HBsAg was 8.8% (n=120). HBsAg-positive subjects were more likely 
to be <48 years of age than older (72.5%) and to be from the northern 
district than the other districts (52.5%). HBsAg positivity tended 
to decrease with increasing age, and the difference was statistically 
significant (p=0.011). There was no significant association between 
sex and HBsAg status, although more males than females were 
affected (9.7% v. 8.3%; p=0.08) (Table 2).
In the multivariate regression analysis, only two risk factors in 
the final model, communal use of a toothbrush and residence in the 
northern district, were significantly associated with HBsAg positivity 
(odds ratio (OR) 2.46, 95% CI 1.45 - 4.18 and OR 2.16, 95% CI 1.31 - 
3.55, respectively) (Table 3).
Characteristics of anti-HCV positive subjects
A total of 1 364 samples were assayed for anti-HCV. The anti-HCV 
prevalence overall was 10.0% (n=137), the prevalence being lowest 
in the southern district (2.8%) and highest in the northern district 
(18.2%). This difference was statistically significant (p<0.001). The 
age group 20 - 37 years (23.4%) was most frequently affected. More 
males than females were anti-HCV-positive (10.7% v. 9.4%) (Table 2). 
In stepwise logistic regression, older age (>57 years) and senatorial 
district showed a significant association with anti-HCV positivity 
in the final model (OR 2.24, 95% CI 1.47 - 3.41 and OR 2.84, 95% 
CI 1.50 - 5.39, respectively) (Table 4).
Characteristics of HIV-positive subjects
A total of 1 350 samples were assayed for HIV. The prevalence of 
HIV was 12.9% (n=174). The highest prevalence was recorded in 
Table 1. Characteristics of the study population (N=1 498)
Variable
Total,
n (%)
Southern district,
n (%)
Central district,
n (%)
Northern district,
n (%)
Design effect-
adjusted p-value 
of difference
Age (yr), median (IQR) 39 (27 - 50) 35 (26 - 45) 40 (30 - 54) 35 (25 - 49) 0.001
Age group (yr), n (%) <0.001
18 - 27 371 (24.8) 156 (29.1) 67 (15.1) 148 (28.6)
28 - 37 310 (20.7) 109 (20.3) 95 (21.4) 106 (20.5)
38 - 47 315 (21) 128 (23.9) 86 (19.3) 101 (19.5)
48 - 57 223 (14.9) 72 (13.4) 74 (16.6) 77 (14.9)
>57 161 (10.7) 26 (4.9) 81 (18.2) 54 (10.5)
Information missing 118 (7.9) 45 (8.4) 42 (9.4) 31 (6)
Sex <0.001
Female 920 (61.4) 350 (65.3) 281 (63.2) 289 (55.9)
Male 536 (35.8) 183 (34.1) 131 (29.4) 222 (42.9)
Information missing 42 (2.8) 3 (0.6) 33 (7.4) 6 (1.2)
Education 1.000
None 128 (8.5) 13 (2.4) 60 (13.5) 55 (10.6)
Primary 275 (18.4) 96 (17.9) 102 (22.9) 77 (14.9)
Secondary 403 (26.9) 166 (31.0) 94 (21.2) 143 (27.7)
Tertiary 462 (30.8) 219 (40.9) 74 (16.6) 169 (32.7)
Information missing 230 (15.4) 42 (7.8) 115 (25.8) 73 (14.1)
Marital status 0.0003
Single 380 (25.4) 138 (25.8) 84 (18.9) 158 (30.6)
Married 888 (59.3) 346 (64.5) 240 (53.9) 302 (58.4)
Divorced 34 (2.3) 11 (2.0) 10 (2.3) 13 (2.5)
Widowed 68 (4.5) 16 (3.0) 26 (5.8) 26 (5.0)
Information missing 128 (8.5) 25 (4.7) 85 (19.1) 18 (3.5)
Number in family <0.001
<5 267 (17.8) 107 (20.0) 95 (21.4) 65 (12.6)
≥5 1 013 (67.6) 381 (71.0) 243 (54.6) 389 (75.2)
Information missing 218 (14.6) 48 (9.0) 107 (24.0) 63 (12.2)
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Table 2. Prevalence of HBV, HCV and HIV by sex, age group and senatorial district
Variable HBV (N=1 365) HCV (N=1 364) HIV (N=1 350)
Prevalence, n (%)
Positive 120 (8.8) 137 (10.0) 174 (12.9)
Negative 1 245 (91.2) 1 227 (90.0) 1 176 (87.1)
Sex, n (%)
Male 47 (9.7) 52 (10.7) 57 (11.8)
Female 70 (8.3) 79 (9.4) 116 (14.0)
Information missing 3 (7.6) 6 (15.3) 1 (2.5)
p-value 0.08 0.07 0.09
Age group (yr), n (%)
18 - 27 36 (30.0) 27 (19.7) 56 (32.2)
28 - 37 30 (25.0) 32 (23.4) 38 (21.8)
38 - 47 21 (17.5) 24 (17.5) 35 (20.1)
48 - 57 16 (13.3) 20 (14.6) 23 (13.2)
>57 9 (7.5) 25 (18.2) 8 (4.6)
Information missing 8 (6.7) 9 (6.6) 14 (8.1)
p-value 0.011 0.149 0.001
Senatorial district
Southern 34 (7.3) 13 (2.8) 109 (23.5)
Central 23 (5.8) 33 (8.3) 25 (6.4)
Northern 63 (12.6) 91 (18.2) 40 (8.1)
p-value 0.001 <0.001 <0.001
Table 3. Regression analysis of risk factors associated with HBV infection
Variable HBsAg-positive, n (%) HBsAg-negative, n (%) Unadjusted OR (95% CI) Adjusted OR (95% CI)
Male 47 (39.2) 437 (35.1) 1.12 (0.81 - 1.75) - 
Age group (28 - 37 yr) 30 (25.0) 265 (20.6) 1.03 (0.62 - 1.72) - 
Family size (≥5) 89 (74.2) 839 (67.4) 1.37 (0.80 - 2.36) - 
Senatorial district 
(northern)
63 (52.5) 436 (35.2) 2.19 (1.33 - 3.59) 2.16 (1.31 - 3.55)
Blood transfusion 18 (15.0) 141 (11.3) 1.40 (0.82 - 2.40) - 
Jaundice 12 (10.0) 106 (8.5) 1.15 (0.60 - 2.21) - 
Share sharps 40 (33.3) 314 (25.2) 1.45 (0.39 - 2.19) - 
Share toothbrush 21 (17.5) 98 (7.9) 2.40 (1.42 - 4.03) 2.46 (1.45 - 4.18)
Scarification/tattoo 17 (14.2) 207 (16.6) 0.79 (0.49 - 1.35) - 
Injection from NHCPs 40 (33.3) 336 (27.0) 1.27 (0.82 - 1.96) - 
Female circumcision 24 (20.0) 233 (18.7) 1.09 (0.63 - 1.89) - 
Multiple sexual partners 17 (14.2) 150 (12.1) 1.14 (0.68 - 1.91) - 
NCHPs = non-certified healthcare practitioners.
Table 4. Regression analysis of risk factors associated with HCV infection
Variable HCV-positive, n (%) HCV-negative, n (%) Unadjusted OR (95% CI) Adjusted OR (95% CI)
Male 52 (37.0) 432 (35.2) 1.16 (0.80 - 1.68) - 
Age group (>57 yr) 25 (18.3) 124 (10.1) 2.43 (1.36 - 4.36) 2.84 (1.50 - 5.39)
Family size (≥5) 93 (67.9) 834 (68.0) 1.15 (0.70 - 1.89) - 
Senatorial district 
(northern)
91 (66.4) 410 (33.4) 2.24 (1.47 - 3.41) 2.96 (1.82 - 4.84)
Blood transfusion 21 (15.3) 138 (11.3) 1.46 (0.89 - 2.42) - 
Jaundice 12 (8.8) 106 (8.6) 0.96 (0.52 - 1.77) - 
Share sharps 28 (20.5) 326 (26.6) 0.70 (0.44 - 1.10) - 
Share toothbrush 9 (6.6) 111 (9.1) 0.68 (0.33 - 1.41) - 
Scarification/tattoo 26 (19.0) 198 (16.1) 1.34 (0.83 - 2.18) - 
Injection from NCHPs 40 (20.9) 336 (27.4) 1.16 (0.79 - 1.71) - 
Female circumcision 39 (28.5) 217 (17.7) 0.79 (0.56 - 1.47) - 
Multiple sexual partners 26 (19.0) 141 (11.5) 1.71 (1.06 - 2.76) 1.47 (0.89 - 2.41)
NCHPs = non-certified healthcare practitioners.
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the southern district (23.5%), followed by the northern and central 
districts (8.1% and 6.5%). The prevalence of HIV infection decreased 
with increasing age, especially in the southern district, with the 18 - 
27-year age group being worst affected. The association between age 
and HIV positivity was statistically significant (p=0.001). Although 
more females than males had a positive HIV result (14.0% v. 11.8%), 
the difference was not statistically significant (p=0.09) (Table 2). 
In multivariate regression analysis, only senatorial district was 
associated with HIV positivity in the final model (OR 3.97, 95% 
CI 2.43 - 6.47) (Table 5).
The prevalences of HBV/HCV, HIV/HBV, HIV/HCV and 
HIV/HBV/HCV co-infection were 1.3%, 1.3%, 1.5% and 0.4%, 
respectively. The rate of HBV/HCV co-infection was highest in 
the northern district (2.6%), that of HIV/HBV co-infection was 
highest in the southern district (1.7%), and that of HIV/HBV/HCV 
co-infection was highest in the central district (0.8%). There was no 
significant variation between co-infection and senatorial districts 
except for HBC/HCV co-infection (p=0.009). Only 19.5% of the 
studied population reported having received vaccination for HBV.
Discussion
HBV, HCV and HIV infections are major public health concerns in 
CRS and Nigeria as a whole, not only because Nigeria is a hyper-
endemic region, but also because individuals infected with these 
viruses may remain asymptomatic for many years and serve as 
reservoir of infection during this period. The need to establish the 
true burden of disease in our various communities therefore cannot 
be over-emphasised. The 8.8% prevalence of HBV in this study is 
high. It is higher than the 5.6% reported among a cross-section of 
hospital staff and volunteers in Calabar, the capital of CRS.[11] The 
difference in prevalence rates could be due to differences in sample 
size, sample population and sampling technique. However, it is 
lower than the national average of 13.6%.[18] The higher national 
prevalence estimate may be modelled on higher rates from other 
parts of the country. Again, most studies on HBV prevalence in 
Nigeria are conducted among high-risk groups such as blood 
donors and patients with liver disease, which may lead to over-
estimation of rates.[21,22]
The observed HIV prevalence of 12.9% indicates a higher 
disease burden in CRS than the 8% recently described by the Cross 
River State Agency for Control of AIDS in 2013, and is also much 
higher than the estimated national average of 3.1%.[8,10] It is likely 
that these data on HIV prevalence in the general population are 
underestimates, because testing for HIV is usually conducted on 
persons who present themselves for voluntary counselling and 
testing. Uptake of HIV testing and counselling is generally reported 
to be low in Nigeria, with only 23% of males and 29% of females 
knowing their status.[17] The situation in CRS is unlikely to be very 
different. Some studies have reported the prevalence of HIV among 
special risk groups such as female sex workers in Nigeria to be 
as high as 27.4%.[17] It is possible that as a result of a widespread 
economic recession and a rise in youth unemployment, formal and 
informal transactional sexual practices and having multiple sexual 
partners for financial benefits, reported to be common among 
young people, may be escalating the prevalence of HIV in CRS. [10] 
The higher prevalence of HIV in the urban southern senatorial 
district compared with the rural central and northern districts is 
similar to findings from other studies that have reported an urban/
rural disparity in HIV prevalence rates.[23]
The HCV prevalence of 10% in this study is similar to figures 
reported previously in CRS, with individuals from the northern 
senatorial district being affected more frequently.[11] Nonetheless, 
it is higher than the national average of 0.5 - 4%.[7] Unhygienic 
practices, common in rural communities in the northern part of 
the state, are thought to be responsible for the high HCV prevalence 
in that region.[11] Although we observed some association between 
certain risk factors such as previous blood transfusion, having 
multiple sexual partners and receiving injections from unqualified 
persons and positive HCV status, the association was not statistically 
significant. Obienu et al.[24] have previously reported that risk factors 
for HCV infection were mostly obscure among Nigerian patients.
Although a higher proportion of our study subjects were female 
than male, more males than females were positive for HBV and 
HCV. The reverse was the case for HIV infection. This is in keeping 
with the national and global trend of unequal gender distribution of 
infections with these viruses.[4,25] The higher prevalence of infection 
with the hepatitis viruses among males is thought to be related to 
the higher clearance rate of these viruses by females compared with 
males.[26,27] The female preponderance of HIV infection has been 
attributed to gender inequality, with females being less likely to be 
able to negotiate safe sex practices.[17]
Individuals aged 18 - 27 years had the highest prevalences of both 
HBV and HIV infection, while older age was associated with HCV 
infection. These are similar to findings from other studies. [1,3-4] Mode 
of transmission, early sexual debut (11 - 15 years) and increased 
sexual activity among 18 - 27-year-olds are postulated as reasons 
Table 5. Regression analysis of risk factors associated with HIV infection
Variable HIV-positive, n (%) HIV-negative, n (%) Unadjusted OR (95% CI) Adjusted OR (95% CI)
Male 57 (32.7) 432 (36.0) 0.83 (0.59 - 1.17) - 
Age group (28 - 37 yr) 38 (21.8) 245 (20.8) 1.92 (0.78 - 4.78) - 
Family size (≥5) 114 (65.5) 802 (68.2) 0.81 (0.54 - 1.22) - 
Senatorial district 
(southern)
109 (62.6) 355 (30.2) 4.64 (2.96 - 7.27) 3.57 (2.13 - 5.42)
Blood transfusion 24 (13.8) 135 (11.5) 1.21 (0.76 - 1.94) - 
Jaundice 21 (12.1) 97 (8.3) 1.42 (0.79 - 2.53) - 
Share sharps 56 (32.2) 294 (25.0) 1.36 (0.96 - 1.94) - 
Share toothbrush 15 (8.6) 101 (8.6) 0.94 (0.54 - 1.65) - 
Scarification/tattoo 26 (14.9) 196 (16.7) 0.84 (0.51 - 1.37) - 
Injection from NCHPs 45 (25.9) 326 (27.7) 0.91 (0.64 - 1.29) - 
Female circumcision 26 (14.9) 22 8 (19.4) 2.16 (1.18 - 3.93) 1.18 (0.65 - 2.12)
Multiple sexual partners 25 (14.4) 140 (11.9) 1.25 (0.78 - 2.01) - 
NCHPs = non-certified healthcare practitioners.
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for this observation. The prevalences of HIV/HBV and HIV/HCV 
co-infection were low in our study compared with other studies. [28] 
This may be due to differences in sample size and sample popu-
lation.
Study limitations
Our study had some limitations. Some of the participants who gave 
consent refused to give a blood sample. This resulted in disparity 
between the total study population and the reported population 
whose blood samples were assayed. The micro-well reader developed 
a technical problem in the course of HIV analysis, resulting in 
incorrect coding of a few results.
Recommendations
We recommend that population-based screening programmes be 
performed in other communities in Nigeria. This will offer the 
opportunity to identify the majority of individuals with undiagnosed 
infections, which is necessary to reduce the national burden of 
disease from complications of these infections such as liver cirrhosis 
and hepatocellular carcinoma in the future.
Conclusions
Our study showed high prevalences of HBV, HCV and HIV infection 
in CRS, and infection was unevenly distributed between the urban 
and rural districts. The burden of HCV in Nigeria may be higher than 
previously documented, especially in rural communities. Population-
based screening guidelines are required to provide vital data that will 
inform optimal national control strategies.
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